Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach.

BACKGROUND In adults, the most lethal and frequent primary brain tumor is glioblastoma. Despite multimodal aggressive therapies, the median survival time after diagnosis is around 15 months. In part, this is due to the blood-brain barrier that restricts common treatments (e.g., chemotherapy). Unfortunately, glioma recurs in 90% of patients. New therapeutic strategies against glioma are urgently required. Substance P (SP), through the neurokinin (NK)-1 receptor, controls cancer cell proliferation by activating c-myc, mitogenactivated protein kinases, activator protein 1 and extracellular signal-regulated kinases 1 and 2. Glioma cells overexpress NK-1 receptors when compared with normal cells. The NK-1 receptor/SP system regulates the proliferation/migration of glioma cells and stimulates angiogenesis, triggering inflammation which contributes to glioma progression. In glioma cells, SP favors glycogen breakdown, essential for glycolysis. By contrast, in glioma, NK-1 receptor antagonists block the proliferation of tumor cells and the breakdown of glycogen and also promote the death (apoptosis) of these cells. These antagonists also inhibit angiogenesis and exert antimetastatic and anti-inflammatory actions. OBJECTIVE This review updates the involvement of the NK-1 receptor/SP system in the development of glioma and the potential clinical application of NK-1 receptor antagonists as antiglioma agents. CONCLUSION The NK-1 receptor plays a crucial role in glioma and NK-1 receptor antagonists could be used as anti-glioma drugs.

• Publication year

  2019

• Venue

  Anti-Cancer Agents in Medicinal Chemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1871520618666180420165401PMID 29692265
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-IL-4/IL-13 for the treatment of asthma: the story so far

  2020cited by this paper
• A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features.

  2018cited by this paper
• Ketamine suppresses the substance P-induced production of IL-6 and IL-8 by human U373MG glioblastoma/astrocytoma cells.

  2017cited by this paper
• Ketamine suppresses the substance P-induced production of IL-6 and IL-8 by human U373MG glioblastoma/astrocytoma cells.

  2017cited by this paper
• Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response

  2017cited by this paper
• Single vs. combination immunotherapeutic strategies for glioma

  2017cited by this paper
• Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis.

  2017cited by this paper
• Drug repurposing for glioblastoma based on molecular subtypes

  2016cited by this paper
• PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

  2016cited by this paper
• Transactivation of Epidermal Growth Factor Receptor by G Protein-Coupled Receptors: Recent Progress, Challenges and Future Research

  2016cited by this paper
• Epidermal growth factor receptor targeting and challenges in glioblastoma.

  2016cited by this paper
• The brain tissue response to surgical injury and its possible contribution to glioma recurrence

  2016cited by this paper
• Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells

  2016cited by this paper
• Limited advances in therapy of glioblastoma trigger re-consideration of research policy.

  2015cited by this paper
• Glioblastoma Stem Cells as a New Therapeutic Target for Glioblastoma

  2015cited by this paper
• Substance P stimulates proliferation of spinal neural stem cells in spinal cord injury via the mitogen-activated protein kinase signaling pathway.

  2015cited by this paper
• Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway

  2015cited by this paper
• The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation

  2015cited by this paper
• The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist.

  2015cited by this paper
• Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.

  2015cited by this paper
• Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous.

  2015cited by this paper
• The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs

  2015cited by this paper
• Substance P enhances the proliferation and migration potential of murine bone marrow-derived mesenchymal stem cell-like cell lines

  2015cited by this paper
• Glioblastoma multiforme: Pathogenesis and treatment.

  2015cited by this paper
• Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.

  2014cited by this paper
• Treatment with the NK1 Antagonist Emend Reduces Blood Brain Barrier Dysfunction and Edema Formation in an Experimental Model of Brain Tumors

  2014cited by this paper
• Cell-Surface Receptors Transactivation Mediated by G Protein-Coupled Receptors

  2014cited by this paper
• A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care

  2013cited by this paper
• Cancer stem cells in glioma: challenges and opportunities.

  2013cited by this paper
• Neurotransmitter Substance P Mediates Pancreatic Cancer Perineural Invasion via NK-1R in Cancer Cells

  2013cited by this paper
• Involvement of substance P and the NK-1 receptor in cancer progression.

  2013cited by this paper
• Safety of neurokinin-1 receptor antagonists

  2013cited by this paper
• Neurokinin-1 Receptor Directly Mediates Glioma Cell Migration by Up-regulation of Matrix Metalloproteinase-2 (MMP-2) and Membrane Type 1-Matrix Metalloproteinase (MT1-MMP)*

  2012cited by this paper
• The Role of Neurokinin-1 Receptor in the Microenvironment of Inflammation and Cancer

  2012cited by this paper
• A Systematic Review of MicroRNA in Glioblastoma Multiforme: Micro-modulators in the Mesenchymal Mode of Migration and Invasion

  2012cited by this paper
• Substance P Induces Rapid and Transient Membrane Blebbing in U373MG Cells in a p21-Activated Kinase-Dependent Manner

  2011cited by this paper
• IL-33 augments substance P–induced VEGF secretion from human mast cells and is increased in psoriatic skin

  2010cited by this paper
• The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug

  2010cited by this paper
• The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile.

  2010cited by this paper
• Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  2009cited by this paper
• A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor‐mediated apoptosis in glioblastomas

  2009cited by this paper
• Targeting growth factors in lung cancer.

  2008cited by this paper
• HIF-1α Is Up-Regulated in Activated Mast Cells by a Process That Involves Calcineurin and NFAT1

  2008cited by this paper
• Cell motility through plasma membrane blebbing

  2008cited by this paper
• Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

  2007cited by this paper
• The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines.

  2005cited by this paper
• Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCδ

  2005cited by this paper
• Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Hemokinin-1 has Substance P-like function in U-251 MG astrocytoma cells: a pharmacological and functional study.

  2005cited by this paper
• Spinal phospholipase A2 in inflammatory hyperalgesia: role of the small, secretory phospholipase A2.

  2005cited by this paper
• Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs

  2004cited by this paper
• Not so strange bedfellows: G-protein-coupled receptors and Src family kinases

  2004cited by this paper
• Enhancement of Angiogenesis by Endogenous Substance P Release and Neurokinin-1 Receptors During Neurogenic Inflammation

  2003cited by this paper
• Neurokinin-1 Receptor Antagonists CP-96,345 and L-733,060 Protect Mice from Cytokine-Mediated Liver Injury

  2003cited by this paper
• Neurokinin-1 Receptor Expression and Its Potential Effects on Tumor Growth in Human Pancreatic Cancer

  2003cited by this paper
• Substance p.

  2001cited by this paper
• Human Stem Cells Express Substance P Gene and Its Receptor

  2000cited by this paper
• Epidermal Growth Factor Receptor Transactivation Mediates Substance P-induced Mitogenic Responses in U-373 MG Cells*

  2000cited by this paper
• Neuropeptides--an overview.

  2000cited by this paper
• Anti-tumour activity of tachykinin NK1receptor antagonists on human glioma U373 MG xenograft

  2000cited by this paper
• Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors

  1999cited by this paper
• Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

  1998cited by this paper
• Distinct mechanism for antidepressant activity by blockade of central substance P receptors.

  1998cited by this paper
• [D-Arg1,D-Trp5,7,9,Leu11]substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells.

  1997cited by this paper
• The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells.

  1997cited by this paper
• Human Astrocytoma Cells (U‐87 MG) Exhibit a Specific Substance P Binding Site with the Characteristics of an NK‐1 Receptor

  1996cited by this paper
• Substance P augments interleukin-10 and tumor necrosis factor-alpha release by human cord blood monocytes and macrophages.

  1996cited by this paper
• [D-Arg1,D-Trp5,7,9,Leu11]Substance P Coordinately and Reversibly Inhibits Bombesin- and Vasopressin-induced Signal Transduction Pathways in Swiss 3T3 Cells*

  1996cited by this paper
• Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway.

  1996cited by this paper
• The war on cancer.

  1996cited by this paper
• Substance‐P receptors in human primary neoplasms: Tumoral and vascular localization

  1995cited by this paper
• Substance P enhances forskolin-stimulated cyclic AMP production in human UC11MG astrocytoma cells.

  1994cited by this paper
• Substance P receptors on human astrocytoma cells are linked to glycogen breakdown.

  1994cited by this paper
• Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in transfected Chinese hamster ovary cells.

  1992cited by this paper
• Ligand Binding Kinetics of Substance P and Neurokinin A Receptors Stably Expressed in Chinese Hamster Ovary Cells and Evidence for Differential Stimulation of Inositol 1,4,5‐Trisphosphate and Cyclic AMP Second Messenger Responses

  1992cited by this paper
• Multiple intracellular signaling pathways of the neuropeptide substance P receptor

  1992cited by this paper
• Granulocyte-macrophage colony-stimulating factor (GM-CSF) production by glioblastoma cells. Despite the presence of inducing signals GM-CSF is not expressed in vivo.

  1992cited by this paper
• Comparative analysis of cytokine patterns in immunological, infectious, and oncological neurological disorders.

  1991cited by this paper
• Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells.

  1990cited by this paper
• Effect of neuropeptides on production of inflammatory cytokines by human monocytes.

  1989cited by this paper
• Effect of neuropeptides on production of inflammatory cytokines by human monocytes

  1988cited by this paper

• NK1R Antagonist, CP‐99,994 Ameliorates Dry Eye Disease via Inhibiting the Plk1‐Cdc25c‐Cdk1 Axis

  2025cites this paper
• Neurokinin-1 receptor antagonists in the current management of chemotherapy-induced nausea and vomiting

  2025cites this paper
• Neuropeptide Signaling in Glioblastoma: A Comprehensive Review of the Current State and Future Direction

  2025cites this paper
• Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma

  2025cites this paper
• Research Progress of NK Cells in Glioblastoma Treatment

  2025cites this paper
• Glioma and Peptidergic Systems: Oncogenic and Anticancer Peptides

  2024cites this paper
• Establishment and validation of glioma patient-derived organoid models

  2024cites this paper
• The in vitro anti‐cancer synergy of neurokinin‐1 receptor antagonist, aprepitant, and 5‐aminolevulinic acid in glioblastoma

  2023influential citation
• Carcinogenesis and Metastasis: Focus on TRPV1-Positive Neurons and Immune Cells

  2023cites this paper
• An Overview of the Molecular Cues and Their Intracellular Signaling Shared by Cancer and the Nervous System: From Neurotransmitters to Synaptic Proteins, Anatomy of an All-Inclusive Cooperation

  2022cites this paper
• The Neurokinin-1 Receptor: A Promising Antitumor Target

  2022cites this paper
• Neurotransmitters: Potential Targets in Glioblastoma

  2022cites this paper
• Immunolocalization of neurokinin 1 receptor in WHO grade 4 astrocytomas, oral squamous cell and urothelial carcinoma.

  2022cites this paper
• The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma

  2022cites this paper
• Cost-effectiveness analysis of antiemetics therapy in breast cancer patients with moderate emetogenic chemotherapy in Prof. Dr. Margono Soekarjo Hospital, Indonesia

  2021cites this paper
• The Role of Tachykinins in the Initiation and Progression of Gastrointestinal Cancers: A Review

  2020cites this paper
• The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia

  2020influential citation
• The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells

  2019cites this paper